- Home
- GLUE vs OLMA Comparison
GLUE vs OLMA Comparison
Compare GLUE & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLUE
- OLMA
- Stock Information
- Founded
- GLUE 2019
- OLMA 2006
- Country
- GLUE United States
- OLMA United States
- Employees
- GLUE N/A
- OLMA N/A
- Industry
- GLUE Biotechnology: Pharmaceutical Preparations
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- GLUE Health Care
- OLMA Health Care
- Exchange
- GLUE Nasdaq
- OLMA Nasdaq
- Market Cap
- GLUE 351.2M
- OLMA 299.7M
- IPO Year
- GLUE 2021
- OLMA 2020
- Fundamental
- Price
- GLUE $4.79
- OLMA $5.33
- Analyst Decision
- GLUE Buy
- OLMA Strong Buy
- Analyst Count
- GLUE 2
- OLMA 4
- Target Price
- GLUE $13.50
- OLMA $24.50
- AVG Volume (30 Days)
- GLUE 468.8K
- OLMA 438.3K
- Earning Date
- GLUE 08-11-2025
- OLMA 08-12-2025
- Dividend Yield
- GLUE N/A
- OLMA N/A
- EPS Growth
- GLUE N/A
- OLMA N/A
- EPS
- GLUE 0.08
- OLMA N/A
- Revenue
- GLUE $159,487,000.00
- OLMA N/A
- Revenue This Year
- GLUE $49.02
- OLMA N/A
- Revenue Next Year
- GLUE N/A
- OLMA N/A
- P/E Ratio
- GLUE $61.82
- OLMA N/A
- Revenue Growth
- GLUE 14889.38
- OLMA N/A
- 52 Week Low
- GLUE $3.50
- OLMA $2.86
- 52 Week High
- GLUE $12.40
- OLMA $16.62
- Technical
- Relative Strength Index (RSI)
- GLUE 40.93
- OLMA 66.85
- Support Level
- GLUE $5.22
- OLMA $4.40
- Resistance Level
- GLUE $5.64
- OLMA $5.36
- Average True Range (ATR)
- GLUE 0.38
- OLMA 0.29
- MACD
- GLUE -0.11
- OLMA 0.07
- Stochastic Oscillator
- GLUE 0.68
- OLMA 93.20
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.